Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of KA2507 in advanced biliary tract cancer (ABC-11)
2019-001459-38Phase 2Terminated
- Sponsor
- Karus Therapeutics
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of KA2507 in biliary cancer, sponsored by Karus Therapeutics. Primary endpoint: Progression-free survival at 4 months. Started Dec 2019; status: terminated.
02
Drugs
KA2507
03
Conditions
biliary cancer
Beyond the preview
Go deeper on 2019-001459-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001459-38.